24 May 2013
Keywords: gsk, avodart, reduces, prostate, cancer, risk, raising
Article | 29 April 2009
UK drug major GlaxoSmithKline's Avodart (dutasteride) lowered the risk of prostate cancer 23% in a high-risk patient population, according to
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
30 April 2009
28 April 2009
23 May 2013
© 2013 thepharmaletter.com